Friday, 16 October 2026European Markets

VAN DE VELDE, SMARTPHOTO GROUP, Another 1 Companies Have A High Dividend Yield And Return On Equity In The Consumer Cyclical Sector.

Loading stream...

(vianews) - van de velde (van.br) is among this list of stock assets with the highest dividend rate and return on equity on the consumer cyclical sector.

financial asset price forward dividend yield return on equity
van de velde (van.br) €33.05 6.93% 22.23%
smartphoto group (smar.br) €26.70 3.76% 11.25%
abeo (abeo.pa) €17.50 2.07% 8.59%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. van de velde (van.br)

6.93% forward dividend yield and 22.23% return on equity

van de velde nv, together with its subsidiaries, designs, develops, manufactures, and markets fashionable luxury lingerie and swimwear for women worldwide. it operates through two segments, business to business (b2b) and direct to consumer (d2c). the company offers its products under the primadonna, marie jo, andres sarda, and lingerie styling brands. it also operates retail websites; stores; and boutiques and department stores. the company was founded in 1919 and is headquartered in schellebelle, belgium. van de velde nv is a subsidiary of van de velde holding nv.

earnings per share

as for profitability, van de velde has a trailing twelve months eps of €2.81.

pe ratio

van de velde has a trailing twelve months price to earnings ratio of 11.76. meaning, the purchaser of the share is investing €11.76 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 22.23%.

volume

today's last reported volume for van de velde is 580 which is 77.91% below its average volume of 2626.

revenue growth

year-on-year quarterly revenue growth declined by 0.2%, now sitting on 211.74m for the twelve trailing months.

volatility

van de velde's last week, last month's, and last quarter's current intraday variation average was a negative 0.10%, a negative 0.18%, and a positive 1.03%.

van de velde's highest amplitude of average volatility was 0.41% (last week), 0.96% (last month), and 1.03% (last quarter).

dividend yield

as stated by morningstar, inc., the next dividend payment is on may 2, 2023, the estimated forward annual dividend rate is 2.28 and the estimated forward annual dividend yield is 6.93%.

more news about van de velde.

2. smartphoto group (smar.br)

3.76% forward dividend yield and 11.25% return on equity

smartphoto group nv engages in the b2c e-commerce business in europe. the company offers personalized products, including gifts, cards, photo books, photo calendars, prints, and wall decoration under the smartphoto brand name. it also engages in the e-commerce distribution of personalized gift packages with chocolate, alcohol, fruit, and flowers under the nayan brand name through websites comprising gift.be and giftsforeurope.com. the company was formerly known as spector photo group nv and changed its name to smartphoto group nv in may 2013. smartphoto group nv was founded in 1964 and is based in wetteren, belgium.

earnings per share

as for profitability, smartphoto group has a trailing twelve months eps of €1.45.

pe ratio

smartphoto group has a trailing twelve months price to earnings ratio of 18.41. meaning, the purchaser of the share is investing €18.41 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 11.25%.

yearly top and bottom value

smartphoto group's stock is valued at €26.70 at 17:30 est, way under its 52-week high of €33.40 and above its 52-week low of €26.40.

more news about smartphoto group.

3. abeo (abeo.pa)

2.07% forward dividend yield and 8.59% return on equity

abéo sa designs, manufactures, and distributes sports and leisure equipment in france and internationally. it offers gymnastics apparatus and landing mats, team sports equipment, physical education, climbing walls, and changing room fittings. it offers its products under the gymnova, janssen-fritsen, spieth gymnastics, schelde sports, spieth america, sportsafe, erhard sport, adec sport, o'jump, cannice, bosan, pcv, vogoscope, bigairbag, entre-prises, clip'n climb, top30, fun spot, climbat, france equipement, meta, prospec, navic, sanitec, suffixe, and sanelite brands. the company was founded in 1955 and is headquartered in rioz, france.

earnings per share

as for profitability, abeo has a trailing twelve months eps of €0.9.

pe ratio

abeo has a trailing twelve months price to earnings ratio of 19.44. meaning, the purchaser of the share is investing €19.44 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 8.59%.

revenue growth

year-on-year quarterly revenue growth grew by 23.2%, now sitting on 227.46m for the twelve trailing months.

volume

today's last reported volume for abeo is 327 which is 61.48% below its average volume of 849.

more news about abeo.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com